Systemic therapy of Cushing’s syndrome

Table 2 Safety profiles of medicines used for the treatment of hypercortisolism in alphabetical order

	CNS	Nerve disorders	Eye disorders	Cardiac disorders	Lung, airways disorders	General disorders and administration site conditions	Liver, Bile disorders	Endocrine disorders	Metabolism and nutrition disorders	Genitalia and mammary gland	Immune system
Aminoglutethimide	XX	XX				XX	X	X	X		X
Cabergoline	XX	XX	X	XX	XX	XX
Etomidate	XX	XX		X	XX	X		X			X
Ketoconazole	X	XX	XX				XX	X		XX	X
Metyrapone		XX						X
Mifepristone		X				X				XX
Mitotane	XX	XX	X			XX	XX	XX	XX	XX
Pasireotide		XX		XX		XX	XX	XX	XX
Rosiglitazone			XX	XX¹		XX	X		XX
Temozolomide	XX	XX	XX	X	XX	XX	XX	X	XX	X
	Gastrointestinal disorders	Kidney, renal or urinary tract disorders	Musculoskeletal and bone disorders	Blood and lymphatic system	Vascular disorders	Skin disorders	CMR	Infectious and parasitic diseases	Psychiatric disorder	Ear and labyrinth disorders
Aminoglutethimide	XX	X		X	X	XX
Cabergoline	XX		X	XX	X	XX
Etomidate	XX		X		XX	XX
Ketoconazole	XX			X		XX
Metyrapone	XX	X		X	XX	X			XX
Mifepristone	XX				X	X		XX
Mitotane	XX	XX	XX	XX	X	XX	XX	X	XX
Pasireotide	XX			XX		XX			XX
Rosiglitazone	XX		XX	XX
Temozolomide	XX	XX	XX	XX	XX	XX	XX	XX	XX	XX

Abbreviations: XX, common, very common; X, rare, uncommon, not known; CMR, carcinogenic, mutagenic and toxic for reproductive system; ¹Rosiglitatzone was suspended for use in the European Union due to an increased cardiovascular risk; method of safety profile assessment: between March and June 2014 SmPCs of currently marketed medicinal products were accessed (if not licensed for treatment of CS, then in other indication; i.e. Ketoconazole, Etomidate, Temozolomide, and Rosiglitazone). If not marketed any more (Aminoglutethimide) or suspended (Rosiglitazone) the last approved SmPC was used.

ISSN: 1750-1172